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The growing interest in cancer metabolism is best demonstrated by the rapid progress made in studying
isocitrate dehydrogenase (IDH) mutations since their discovery just over a year ago. In a recent study
published in Nature, Dang et al. identified 2-hydroxyglutarate as a product of tumor-associated IDH mutants
with potential oncogenic activities.It is now almost a century since the
studies that first associated cellular meta-
bolic changes with cancer. However, the
recognition of a causal connection be-
tween metabolic alterations and cancer
formation was revealed only this decade.
Ironically, it was genetics, rather than
biochemistry, that enabled this break-
through when genes encoding mitochon-
drial enzymes of the tricarboxylic acid
(TCA) cycle, succinate dehydrogenase
(SDH) and fumarate hydratase (FH), were
identified as bona fide tumor suppressors
(King et al., 2006). Over the past year, new
genetic studies placed another metabolic
enzyme, isocitrate dehydrogenase (IDH),
in the spotlight of cancer biology (Yan
et al., 2009a). High-throughput sequenc-
ing revealed that two of the three isoforms
of IDH (IDH1 and IDH2) are mutated in
high proportions in gliomas (Parsons
et al., 2008; Yan et al., 2009b). However,
unlike SDH and FH, IDH mutations do
not follow Knudson’s two-hit model of
tumor suppressor genes. In the new
study, Dang et al. (2009) demonstrated
that although IDH1 mutants lose their
normal enzymatic activity in tumors, they
gain a new one, generating a new pro-
duct, 2-hydroxyglutarate, with potentially
tumor-supporting actions (making it an
onco-metabolite).
Eukaryotic cells contain two classes of
IDH enzymes according to dependence
on either NAD+ or NADP+. These enzymes
normally convert isocitrate to a-ketogluta-
rate (aka 2-oxoglutarate), with the concur-
rent reduction of NAD(P)+ to NAD(P)H
(Figure 1). The two NADP+-dependent
forms, IDH1 and IDH2, are cytosolic and
mitochondrial, respectively. IDH3, the
only NAD+-dependent IDH, is located atthe mitochondria and is part of the TCA
cycle. Rapid cycling of metabolites be-
tween cytosol and mitochondria is a
common feature of cellular metabolism.
Metabolites entering the mitochondria
can be processed for energy generation
usually through the production of NADH
in the TCA cycle whereas metabolites
exported back to the cytosol take part in
anabolic processes. The transport of
metabolites is also coupled to electron
exchange between mitochondrial and
cytosolic NADH and NADPH, both of
which cannot move across the mitochon-
drial inner membrane (Figure 1). Because
mitochondrial NADH operates in energy
metabolism and cytosolic NADPH func-
tions in anabolic processes and redox
control, it is reasonable to expect
changes in one or all of these processes
in tumors carrying an IDH mutation.
Until now, only mutations in IDH1 and 2
were found in cancers, therefore leaving
the TCA cycle untouched (Yan et al.,
2009a). IDH1 mutations form the lion’s
share of IDH mutations found in cancer,
with IDH2 mutation being much less
common. So far, gliomas have been
shown as the cancer type most likely to
contain IDH mutations. Interestingly,
they seem to arise early in the develop-
ment of a glioma, suggesting that it con-
fers advantage early on in tumor progres-
sion. One of the most striking features of
IDH1 and 2 mutations is that it is always
the same residue that is mutated: R132
in IDH1 and R172 in IDH2. These residues
create the hydrophilic interactions that
allow the binding of isocitrate (Xu et al.,
2004). The residues that are substituted
for arginine are wide ranging, which
strongly suggests that it is not the newCancer Cellresidue, but the replacement of the
arginine, which supports tumorigenesis
by impairing isocitrate binding. Indeed,
loss of IDH function was reported for
these mutants and therefore IDH was
suggested to be a tumor suppressor
(Zhao et al., 2009). However, the fact
that mutations were observed only on
specific arginine residues and only on
one allele of IDH1/2with the other remain-
ing wild-type (WT) led to the hypothesis
that these are, in fact, gain- rather than
loss-of-function mutations with onco-
genic potential.
The newwork (Dang et al., 2009) started
with large-scale metabolite quantification
(metabolomics) of cells expressing either
WT or tumor-derived mutant of IDH1
(R132H). Only one significant metabolic
change was observed in mutant-IDH1-
expressing cells, which was a large
accumulation of 2-hydroxyglutarate, a
reduced formofa-ketoglutarate (Figure 1).
Indeed, Dang et al. confirmed that the
carbon backbone of the accumulated
2-hydroxyglutarate is derived from gluta-
mine, the major source of a-ketoglutarate
in these cells (Figure 1). These results
suggest that the mutant IDH1 changed
its substrate specificity and directionality.
In vitro enzymatic analysis confirmed this;
whereas WT IDH1 converted isocitrate to
a-ketoglutarate, several tumor-associ-
ated mutants of IDH1 could no longer
catalyze this reaction and instead reduced
a-ketoglutarate to 2-hydroxyglutarate (but
not to isocitrate). Structural comparison of
the mutant and WT IDH1 revealed that
mutations in R132 change the orientation
of the catalytic site so the enzyme binds
NADPH with higher affinity, a feature
that supports reductase rather than17, January 19, 2010 ª2010 Elsevier Inc. 7
Figure 1. The Roles of IDH Enzymes in the Exchange of Metabolites between
the Mitochondria and the Cytosol, and Their Potential Role in Tumorigenesis
Many isoforms of TCA cycle enzymes (light blue) also operate in the cytosol. They are important for
synchronizing bioenergetic and anabolic needs by directing TCA cycle metabolites and electrons, in
the forms of NAD(P)H, in and out the mitochondria (red). The two major carbon sources for these metab-
olites are glucose and glutamine, which are catabolized via glycolysis (green) and glutaminolysis (purple),
respectively. The three IDH isoenzymes are important players in these processes. IDH3 is part of the TCA
cycle where it generates NADH as a fuel for energy production while IDH1 and 2 are important for shuttling
electrons between the mitochondria and the cytosol. Although mutations in IDH1 are expected to hinder
these processes, newly described work (Dang et al., 2009) proposes a new gain-of-function role for
glioma-associated mutants of IDH1. R132mutations of IDH1 generate a new enzyme with a-ketoglutarate
reductase activity that produces 2-hydroxyglutarate and increased 2-hydroxyglutarate strongly correlates
with cancer formation. But the tumorigenic mechanism is not yet understood. One possibility may be that
2-hydroxyglutarate inhibits PHD activity by competing with a-ketoglutarate binding.
Solid or dashed lines indicate direct or indirect metabolic links, respectively.
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Previewsoxidase activity. Furthermore, modeling
a-ketoglutarate into the structure
suggests a new orientation of the binding
to a-ketoglutarate that can explain the
formation of a new product, rather than
simply running the reaction in reverse.
Finally, Dang et al. demonstrated that
2-hydroxyglutarate levels are 100-fold
higher in human gliomas that carry R132
mutations of IDH1 than in tumors with
WT IDH1.
These results revealed a new gain-of-
function activity of the tumor-derived
IDH1 mutants and strongly correlated
the levels of 2-hydroxyglutarate with
tumorigenesis. However, does this grant
2-hydroxyglutarate the title ‘‘onco-metab-
olite’’ as Dang et al. proposed? What
might be these oncogenic functions of
2-hydroxyglutarate?8 Cancer Cell 17, January 19, 2010 ª2010 ElThe loss of activity of two other TCA
cycle enzymes mentioned earlier, SDH
or FH, supports tumor formation by
increasing the levels of their respective
TCA cycle substrates, succinate or fuma-
rate. These substrates inhibit the oxygen-
sensing enzymes hypoxia-inducible
factor prolyl hydroxylases (PHDs) by com-
peting with their cosubstrate a-ketogluta-
rate (MacKenzie et al., 2007). PHD inhibi-
tion leads to the activation of the HIF
transcription factor among other, less
characterized, effects (King et al., 2006).
It was previously demonstrated that
PHDs are inhibited in cells carrying
mutant IDH1 (Zhao et al., 2009). There-
fore, it is possible that like succinate and
fumarate, 2-hydroxyglutarate inhibits
PHD activity by competing with a-keto-
glutarate (Figure 1). The observation thatsevier Inc.cell-permeable a-ketoglutarate esters
prevent HIF activation in cells expressing
mutant IDH1 (Zhao et al., 2009) supports
this model.
The normal metabolic role of 2-hydrox-
yglutarate is not completely understood
but 2-hydroxyglutarate is not unnatural
to cells. It can be generated by spe-
cific a-ketoglutarate reductase enzymes
(Struys, 2006) and oxidized back to
a-ketoglutarate by 2-hydroxyglutarate
dehydrogenases (2HGD) (Figure 1). The
picture is further complicated by the exis-
tence of two enantiomers of 2-hydroxy-
glutarate with specific 2HGD for each.
Mutations in 2HGD cause pathological
accumulation of 2-hydroxyglutarate with
different clinical features based on the
enantiomer involved. Pathological accu-
mulation of the L-2-hydroxyglutarate
enantiomer is characterized by progres-
sive neuronal defects and was recently
linked to increased risk of brain tumors
including gliomas (Aghili et al., 2009).
This is strong support for the potential
oncogenic role of 2-hydroxyglutarate,
but with one caveat: Dang et al. demon-
strated that mutant IDH1 generates
D-2-hydroxyglutarate and not the L enan-
tiomer. Accumulation of D-2-hydroxyglu-
tarate is observed in D-2HGD-deficient
patients and is associated with encepha-
lopathy, cardiomyopathy, and more—
but, so far, not with tumors (Struys,
2006). It is possible that D-2-hydroxyglu-
tarate, when reaching very high levels, is
too toxic to have tumorigenic potential.
This could have therapeutic significance
because it may suggest that a small and
transient pharmacological inhibition of
2HGD, by raising the levels of 2-hydroxy-
glutarate from protumorigenic to toxic,
could specifically kill gliomas with IDH1
mutations.REFERENCES
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Cells exposed to genotoxic insults such as ionizing radiation activate a signaling cascade to repair the
damaged DNA. Two recent articles published in Nature show that such genome maintenance requires modi-
fications of tumor suppressor proteins BRCA1 and 53BP1 by the small ubiquitin-like modifier SUMO.Proper genome maintenance, ensured by
the cellular DNA damage response (DDR)
machinery, is a prerequisite for normal
development andprevention of premature
aging and diverse devastating diseases
including cancer (Jackson and Bartek,
2009). Indeed, one reason for cancer inci-
dencenot beingevenhigher appears tobe
the intrinsic ability of our cells to detect
and deal with the DNA damage caused
by exogenous genotoxic agents such as
radiation or chemicals as well as endoge-
nous sources such as oncogene-evoked
replication stress and telomere erosion
during the early stages of cancer develop-
ment (Halazonetis et al., 2008; Jackson
and Bartek, 2009). Even if some DNA
lesions, such as subsets of DNA double-
strand breaks (DSB) that occur commonly
during tumorigenesis, remain unrepaired,
sustained signaling and effector path-
ways within the DDR ‘‘anticancer barrier’’
machinery usually eliminate such haz-
ardous, genetically unstable cells by
inducing cell death or a permanent cell
cycle arrest known as cellular senescence
(Halazonetis et al., 2008).
From the mechanistic viewpoint, sens-
ing, signaling, and repair of DSBs involvea plethora of proteins whose sequential
accrual and function at the DNA damage
sites is modulated by a myriad of post-
translational modifications, including
phosphorylation, acetylation, methyla-
tion, and ubiquitylation, which are highly
dynamic and reversible. The phosphoryla-
tion/dephosphorylation events are per-
formed by kinases such as the ATM, ATR,
and DNA-PK, and several protein phos-
phatases (Jackson andBartek, 2009). The
emerging ubiquitylation cascade com-
prises the E3 ubiquitin ligases RNF8,
RNF168, and BRCA1, as well as the E2
ubiquitin-conjugating enzyme UBC13 and
the candidate assembly factor HERC2
(Bergink and Jentsch, 2009; Bekker-Jen-
sen et al., 2010). Unlike the classical
role of ubiquitylation in triggering protein
degradation, however, this ubiquitin-medi-
ated pathway orchestrates protein-protein
interactions on damaged chromosomes
and recruitment of the key DNA repair fac-
tors 53BP1 and BRCA1 to DSBs, thereby
promoting genomic integrity (Figure 1).
Despite the rapid progress in under-
standing the molecular basis of DSB
signaling and repair, more surprises are
in store for us in this lively area ofresearch, as illustrated by two recent
reports in Nature (Galanty et al., 2009;
Morris et al., 2009). These exciting studies
provide evidence for a key role of yet
another protein modification, sumoylation
(covalent attachment of the small proteins
known as SUMO1, SUMO2, and SUMO3),
in coordinating the DNA damage re-
sponse to DSBs (Figure 1). Processes
critical for cell fate decisions including
survival and some aspects of DNA repair
have been linked to the sumoylation
pathway, particularly in yeast (Bergink
and Jentsch, 2009; Branzei and Foiani,
2008; Hay, 2005). However, the involve-
ment of the sumoylation pathway in DSB
response and its functional interplay with
the ubiquitylation cascade that controls
recruitment of 53BP1 and BRCA1 are
novel and very relevant for genome main-
tenance and protection against cancer.
So what is revealed by the two new
studies? First, in a complementary series
of immunofluorescenceand live-cell imag-
ing experiments, they show that the
SUMO1 and SUMO2/3 conjugates, as
well as the E1 (SAE1), E2 (UBC9), and E3
(PIAS1 and PIAS4) sumoylation enzymes,
all rapidly accumulate at the sites of DNA17, January 19, 2010 ª2010 Elsevier Inc. 9
